



The ENERGY 2 Study

Investigating BMN 401 *, a subcutaneous ENPP1 enzyme therapy, for infants with GACI Type 1



Generalized Arterial Calcification of Infancy (GACI) is a rare, severe disease caused by mutations in the *ENPP1* (Type 1) or *ABCC6* (Type 2) genes that leads to high cardiovascular morbidity and mortality.¹

There are currently no approved therapies for GACI.²



Study design³

- Phase 3, open-label study ([EUCT 2024-512991-36-00](#))
- To determine if BMN 401 increases inorganic pyrophosphate (PPi) levels and overall survival



Select enrollment criteria³

- Birth (newborn) to <1 year of age at baseline
- Confirmed postnatal genetic diagnosis of *ENPP1* with biallelic mutations (ie, homozygous or compound heterozygous)



Study duration³

≤60-day screening period | 52-week treatment period | Follow-up extension period

* Formerly INZ-701. BMN 401 is an investigational product and has not been determined to be safe or effective by the US Food and Drug Administration or any other health regulatory authority

Available Sites³



Hôpital Necker-Enfants Malades

Paris, France

Principal Investigator:

Prof. Damien Bonnet

damien.bonnet@aphp.fr



King Faisal Specialist Hospital and Research Centre (KFSHRC)

Riyadh, Kingdom of Saudi Arabia

Principal Investigator:

Dr Afaf Alsagheir

asagheir@kfshrc.edu.sa



University of Debrecen Hospital

Debrecen, Hungary

Principal Investigator:

Dr Andrea Berkes

berkes.andrea@med.unideb.hu



Ümraniye Training and Research Hospital

Istanbul, Türkiye

Principal Investigator:

Prof. Dr Taliha Öner

talihaoner@yahoo.com



Azienda Ospedaliera Universitaria Meyer IRCCS

Florence, Italy

Principal Investigator:

Prof. Iacopo Olivetto

iacopo.olivetto@unifi.it



Royal Manchester Children's Hospital

Manchester, United Kingdom

Principal Investigator:

Dr Amish Chinoy

amish.chinoy@mft.nhs.uk



Sant Joan De Deu Barcelona Hospital

Esplugues De Llobregat, Spain

Principal Investigator:

Dr Pedro Arango Sancho

pedro.arango@sjd.es



Hospital Universitário Pedro Ernesto

Rio de Janeiro, Brazil

Principal Investigator:

Dr Ana Bordallo

anapaulabordallo@gmail.com

Your patients with GACI Type 1 (ENPP1 Deficiency) may be eligible to participate.

References: 1. Ferreira CR, et al. *JBMR Plus*. 2025;9(5):z1af019.
2. Galletti S, et al. *JIMD Rep*. 2011;1:23–27. 3. EUCT 2024-512991-36-00:
<https://euclinicaltrials.eu/ctis-public/view/2024-512991-36-00>, accessed 18Feb2026.

©2026 BioMarin Pharmaceutical Inc. All rights reserved. MED-BM-0295

B:OMARIN